Piper Sandler reiterated an Overweight rating on Compass Therapeutics, noting the company focuses on developing therapies in the oncology sector and is viewed favorably regarding AI stocks.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Piper Sandler reiterated an Overweight rating on Compass Therapeutics, noting the company focuses on developing therapies in the oncology sector and is viewed favorably regarding AI stocks.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Piper Sandler Companies
American financial services company
Coverage
Newest first; wire copies grouped- Insider MonkeyPiper Sandler Reaffirms Optimism on Compass Therapeutics (CMPX) Amid Trial Update Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the must-buy penny stocks to invest in. On August 18, Piper Sandle